136 related articles for article (PubMed ID: 2476484)
1. Several antigenic determinants exposed on the gp120 moiety of HIV-1 gp160 are hidden on the mature gp120.
Thiriart C; Francotte M; Cohen J; Collignon C; Delers A; Kummert S; Molitor C; Gilles D; Roelants P; van Wijnendaele F
J Immunol; 1989 Sep; 143(6):1832-6. PubMed ID: 2476484
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of monoclonal antibodies to HIV-1 envelope by neutralization and binding assays: an international collaboration.
D'Souza MP; Geyer SJ; Hanson CV; Hendry RM; Milman G
AIDS; 1994 Feb; 8(2):169-81. PubMed ID: 7519019
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and epitope mapping of a recombinant soluble gp160 of the human immunodeficiency virus type 1 envelope glycoprotein.
Pasquali JL; Kieny MP; Kolbe H; Christmann D; Knapp AM
AIDS Res Hum Retroviruses; 1990 Sep; 6(9):1107-13. PubMed ID: 1702300
[TBL] [Abstract][Full Text] [Related]
4. [HIV-1 env glycoprotein gp120 and gp160 expressed in vaccinia virus system and their antigenicity analysis].
Chen Y; Garcia R; Baralle FE
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1997 Apr; 19(2):120-6. PubMed ID: 10453506
[TBL] [Abstract][Full Text] [Related]
5. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
[TBL] [Abstract][Full Text] [Related]
6. Murine monoclonal antibodies biologically active against the amino region of HIV-1 gp120: isolation and characterization.
Dickey C; Ziegner U; Agadjanyan MG; Srikantan V; Refaeli Y; Prabhu A; Sato A; Williams WV; Weiner DB; Ugen KE
DNA Cell Biol; 2000 Apr; 19(4):243-52. PubMed ID: 10798448
[TBL] [Abstract][Full Text] [Related]
7. Human immunodeficiency virus gp120 glycoprotein detected by a monoclonal antibody to a synthetic peptide.
Chanh TC; Kennedy RC; Alderete BE; Kanda P; Eichberg JW; Dreesman GR
Eur J Immunol; 1986 Nov; 16(11):1465-8. PubMed ID: 3023102
[TBL] [Abstract][Full Text] [Related]
8. Anti-idiotypic antibodies to the third variable domain of gp120 induce an anti-HIV-1 antibody response in mice.
Boudet F; Theze J; Zouali M
Virology; 1994 Apr; 200(1):176-88. PubMed ID: 7510435
[TBL] [Abstract][Full Text] [Related]
9. Sensitive ELISA for the gp120 and gp160 surface glycoproteins of HIV-1.
Moore JP; Jarrett RF
AIDS Res Hum Retroviruses; 1988 Oct; 4(5):369-79. PubMed ID: 2848557
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccines expressing soluble CD4-envelope proteins fused to C3d elicit cross-reactive neutralizing antibodies to HIV-1.
Bower JF; Green TD; Ross TM
Virology; 2004 Oct; 328(2):292-300. PubMed ID: 15464849
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic and antigenic properties of an HIV-1 gp120-derived multiple chain peptide.
Kelker HC; Schlesinger D; Valentine FT
J Immunol; 1994 Apr; 152(8):4139-48. PubMed ID: 8144976
[TBL] [Abstract][Full Text] [Related]
12. Recombinant human immunodeficiency Pr55gag virus-like particles presenting chimeric envelope glycoproteins induce cytotoxic T-cells and neutralizing antibodies.
Deml L; Schirmbeck R; Reimann J; Wolf H; Wagner R
Virology; 1997 Aug; 235(1):26-39. PubMed ID: 9300034
[TBL] [Abstract][Full Text] [Related]
13. Antigenic properties of recombinant envelope glycoproteins derived from T-cell-line-adapted isolates or primary human immunodeficiency virus isolates and their relationship to immunogenicity.
Brand D; Lemiale F; Thibault G; Verrier B; Lebigot S; Roingeard P; Buzelay L; Brunet S; Barin F
Virology; 2000 Jun; 271(2):350-62. PubMed ID: 10860888
[TBL] [Abstract][Full Text] [Related]
14. HIV envelope glycoprotein-induced cell killing by apoptosis is enhanced with increased expression of CD26 in CD4+ T cells.
Jacotot E; Callebaut C; Blanco J; Rivière Y; Krust B; Hovanessian AG
Virology; 1996 Sep; 223(2):318-30. PubMed ID: 8806567
[TBL] [Abstract][Full Text] [Related]
15. Design of immunogens that present the crown of the HIV-1 V3 loop in a conformation competent to generate 447-52D-like antibodies.
Chakraborty K; Durani V; Miranda ER; Citron M; Liang X; Schleif W; Joyce JG; Varadarajan R
Biochem J; 2006 Nov; 399(3):483-91. PubMed ID: 16827663
[TBL] [Abstract][Full Text] [Related]
16. HIV experimental vaccines based on the iscom technology using envelope and GAG gene products.
Akerblom L; Nara P; Dunlop N; Putney S; Morein B
Biotechnol Ther; 1993; 4(3-4):145-61. PubMed ID: 8292967
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a monoclonal antibody specific for the HIV-1 precursor glycoprotein.
Krust B; Laurent AG; Le Guern A; Jeannequin O; Montagnier L; Hovanessian AG
AIDS; 1988 Feb; 2(1):17-24. PubMed ID: 2833905
[TBL] [Abstract][Full Text] [Related]
18. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
[TBL] [Abstract][Full Text] [Related]
19. Recognition of HIV glycoprotein gp120 by T cells. Role of monocyte CD4 in the presentation of gp120.
Siliciano RF; Knall C; Lawton T; Berman P; Gregory T; Reinherz EL
J Immunol; 1989 Mar; 142(5):1506-11. PubMed ID: 2537355
[TBL] [Abstract][Full Text] [Related]
20. Selective recognition of oligomeric HIV-1 primary isolate envelope glycoproteins by potently neutralizing ligands requires efficient precursor cleavage.
Pancera M; Wyatt R
Virology; 2005 Feb; 332(1):145-56. PubMed ID: 15661147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
